SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biosource International
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mike mulhearn who wrote (72)3/11/1997 6:47:00 PM
From: mike mulhearn   of 696
 
Subj: Re: New Products
Date: Fri, 21 Feb 1997 13:20:46 EST
From: DMoore6797
Message-ID: <19970221182000.NAA13307@ladder02.news.aol.com>

I had an opportunity to go to recent conference and meet the CEO at a breakout session.As previously noted, the new molecular diagnostics business should have high margins , presumably because of a lack of competing products. He further noted that the new technology is many months further along in the timetable that was previously reported secondary to the efforts of Dr. Reagan He was quite optimistic about the new diagnostics business.
Mr. Chamberlain discussed briefly the strategy for another aquisition and has had very preliminary communications but emphasized the rigid criteria he would utilize. Aquisition for the sake of aquisition is not in the cards Regarding current valuation, he felt that a current market cap of approx 100 million ( 12 $ / share ) was appropriate. As the new business evolves according to expectation, approximately 16 $ per share.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News